CYP1A2

Cytochrome P450 1A2 · P05177 · CYP1A2 on Sugi Atlas →

2,695,541 patent compounds predicted against CYP1A2, 1,570,853 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3075	0.67	9/20
SCHEMBL5531	0.49	8/20
Nifedipine (SCHEMBL3968)	1.00	6/20
Procaine (SCHEMBL3524)	0.67	6/20
Fluconazole (SCHEMBL3151)	0.53	6/20
SCHEMBL2646	0.48	6/20
Miconazole (SCHEMBL2866)	1.00	5/20
(R)-Miconazole (SCHEMBL2867)	1.00	5/20
Propranolol (SCHEMBL3955)	1.00	5/20
Levopropranolol (SCHEMBL3956)	1.00	5/20
Pindolol (SCHEMBL5219)	1.00	5/20
Pindolol (SCHEMBL5220)	1.00	5/20
Miconazole (SCHEMBL3366)	0.98	5/20
(R)-Miconazole (SCHEMBL3367)	0.98	5/20
Alpha-Naphthylisocyanate (SCHEMBL374)	0.64	5/20
Aluminum Clofibrate (SCHEMBL3344)	0.62	5/20
SCHEMBL1218	0.58	5/20
SCHEMBL1643	0.58	5/20
Pentachlorophenol (SCHEMBL1492)	0.53	5/20
SCHEMBL2647	0.48	5/20

Clinical trials — most relevant to CYP1A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	PHASE2	COMPLETED
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants	PHASE1	COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
Pharmacokinetics of BF2.649 in Renal Impairment	PHASE1	COMPLETED
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects	PHASE1	COMPLETED
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers	PHASE1	COMPLETED
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function	PHASE1	COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function	PHASE1	COMPLETED
Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165	PHASE1	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
CYP2C19 Variants and Limonene Metabolism	nan	RECRUITING
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics	nan	COMPLETED
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients	nan	UNKNOWN
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP1A2 binder may also engage these)

Protein	Name	Similarity
O77809	—	1.000	O77809 →
Q5KQT6	—	1.000	Q5KQT6 →
Q5RBQ1	—	1.000	Q5RBQ1 →
O77810	—	1.000	O77810 →
Q3LFT9	—	0.998	Q3LFT9 →
Q4H4C3	—	0.997	Q4H4C3 →
Q00557	—	0.995	Q00557 →
P56592	—	0.994	P56592 →
P00187	—	0.994	P00187 →
P00185	—	0.993	P00185 →
Q64391	—	0.993	Q64391 →
P56590	—	0.993	P56590 →
P79761	—	0.992	P79761 →
P00184	—	0.991	P00184 →
P05176	—	0.990	P05176 →
Q3LFU0	—	0.989	Q3LFU0 →
Q06367	—	0.989	Q06367 →
P33616	—	0.987	P33616 →
Q6GUR1	—	0.986	Q6GUR1 →
CYP1A1	Cytochrome P450 1A1	0.986	landscape →
Q5KQT7	—	0.986	Q5KQT7 →
P04799	—	0.986	P04799 →
P24453	—	0.985	P24453 →
P79760	—	0.984	P79760 →
P00186	—	0.983	P00186 →
P56591	—	0.982	P56591 →
Q0IIF9	—	0.980	Q0IIF9 →
Q92148	—	0.977	Q92148 →
Q92116	—	0.977	Q92116 →
P79716	—	0.976	P79716 →